Abstract
Primary treatment of endometrial cancer is surgical, but adjuvant radiation therapy (RT) and chemotherapy (CT) have been shown to decrease the incidence of locoregional recurrences. Despite current treatments including postoperative RT or CT, survival in high-risk endometrial cancer remains poor with a high rate of distant metastatic disease. This Phase II study examines the safety and toxicity of postoperative concomitant chemoradiation (ChemoRT) and adjuvant chemotherapy in patients with high-risk endometrial carcinoma as well as the patterns of recurrence and survival.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
